AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05931471 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yogurt Intervention
Description: Participants will be provided with a commercial yogurt that contains only cultured dairy, traditional live active cultures (Streptococcus thermophilus, Lactobacillus delbrueckii subsp. bulgaricus, and possibly other non-brand-specific strains), sugar, and, optionally, vanilla flavor. The yogurt will contain no starches or pectin, gums, fiber or other added ingredients. Participants will be asked to consume two 6-ounce portions of yogurt each day, and to log their consumption in a provided booklet. They will be advised to incorporate the yogurt into their diet however they choose (as part of meals or as snacks), to avoid other fermented foods, and to otherwise maintain their habitual diet.
Study NCT05469425 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preoperative home-based exercise training
Description: Home-based aerobic and resistance exercise training (preoperative period)~Dose of aerobic exercise:~1. Type: Walking~2. Frequency: 3 sessions per week~3. Duration: 30 minutes~4. Intensity: Rate of perceived exertion on Borg Category Ratio-10 (3-5)~5. Progression: Increase the walking duration in 10 minutes (after week 2)~Dose of resistance exercise:~1. Type: Six exercises for upper and lower limbs using bodyweight and free-wights of 1-2kg~2. Frequency: 2 sessions per week~3. Duration: 2 sets x 15 repetitions~4. Rest in-between sets: 45 seconds~5. Intensity: Rate of perceived exertion on Borg Category Ratio-10 (3-5)~6. Progression: Increase the number of sets (3 sets of 15 repetitions after week 2)~Weekly telephone supervision: A physical therapist will carry out weekly telephone calls with all participants to monitor adverse events and recommend strategies to overcome barriers that arise during the exercise program.
Study NCT05488106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin 5mg/d
Description: Riboflavin 5mg/d
Study NCT05488106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin 20mg/d
Description: Riboflavin 20mg/d
Study NCT06461286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PYC-001
Description: Single Group Assignment
Study NCT05563766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole 300 mg po bid for two weeks prior and 6-8 weeks after completion of standard of care neoadjuvant chemoradiation
Study NCT06355063 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CellFX® nsPFA™ Cardiac Surgery System
Description: Adult patients presenting to the investigational center that are to undergo non-emergent concomitant cardiac surgical procedure(s), scheduled to be performed on cardiopulmonary bypass including open-heart surgery for one or more of the following: mitral valve repair or replacement, aortic valve repair or replacement, ascending aortic aneurysms, or coronary artery bypass procedures with history of documented atrial fibrillation within one year prior to enrollment will be evaluated for eligibility and participation in the study.
Study NCT04612244 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FARAPULSE Pulsed Field Ablation System
Description: Ablation using the FARAPULSE Pulsed Field Ablation System
Study NCT04612244 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RadioFrequency and Cryoballoon Ablation
Description: Contact Force Enabled RF and Cryoballoon ablation catheters indicated for Paroxysmal Atrial Fibrillation
Study NCT06383572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV
Study NCT06383572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate
Description: Given by IV
Study NCT06383572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given by IV
Study NCT06549296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RD06-04 CART Cell Injection
Description: CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide.
Study NCT05477251 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microwave ablation
Description: MWA procedures were performed under local anesthesia and CT guidance (GE Discovery CT750 HD) was used for the guidance. Using the coaxial system, MWA was performed by the combining of a 17G sharp-tip guide trocar needle and a 15-cm cooled-shaft electrode (18-gauge) with a 1.5-cm expandable blunt-tip (MTC-3CA-II3, Vison Medical Inc.). Firstly, the sharp-tip guide trocar needle was used to puncture through the pleura and then the blunt-tip MWA electrode was advanced into the GGO lesion through the guide needle lumen. Once the target was reached, ablation was performed at a power of 40 watts. Once the lesion was covered by the ablation zone, the ablation completed.
Study NCT06405841 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: All patients will be asked to complete a survey at 1, 2, 4, 12 and 24 weeks from the trauma to assess their quality of life
Study NCT06405841 — intervention group
Intervention type: OTHER
Intervention: Pain management
Description: All patients will be asked about their pain management at 1, 2, 4, 12 and 24 weeks from the trauma to assess if they are under medication and what kind of medication are they taking
Study NCT05824871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sudapyridine
Description: Sudapyridine (WX-081) will be administered as a loading dose for 2 weeks (450 mg once daily for 7 days, followed by 300 mg once daily for 7 days) and a maintenance dose (150 mg once daily) from Week 3 to Week 24. The intervention is combined with background regimen (BR) and placebo for bedaquiline.
Study NCT05824871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bedaquiline
Description: Bedaquiline will be administered as a loading dose for 2 weeks (400 mg once daily) and a maintenance dose (200 mg three times per week, with at least 48 hours between doses) from Week 3 to Week 24. The intervention is combined with background regimen (BR) and placebo for Sudapyridine.
Study NCT06527755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplontersen Solution for Injection
Description: an autoinjector with 0.8 mL deliverable volume (at 56 mg/mL concentration) will be provided, total dose is 45 mg.
Study NCT04929795 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rhythmic auditory stimulation (RAS)
Description: The song named 'Sign of The Times' is played and recorded by the research personnel beforehand. The beat of the song will serve as RAS. The computer software Audacity will be used to adjust tempi of RAS. Before intervention, the participant is required to execute the movement task without the aid of RAS as quickly as possible for 30 seconds, so that we obtain his/her baseline movement tempo. For each 40-minute training session in the first training week, three RAS tempi will be provided for the first, second, and last 10 minutes with a five-minute break in between: normal (100% of the baseline tempo), quick (105% of the baseline tempo), and fast (110% of the baseline tempo). With each training week, the three RAS tempi will be increased by 5%. Participants in the experimental groups are required to use their right hand to pick up beads from source bowls to the target bowl when listening to the song. The 3-week intervention program will include 21 40-minute daily training sessions.
Study NCT04929795 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: no RAS
Description: The training protocol will be the same as that used in the experimental group except the lack of RAS during execution of the movement task.
Study NCT05208125 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1.HTI at week 0, ConM SOSIP.v7 at weeks 4, 12 and 28, and MVA.HTI at week 22 (CSSMS).
Description: Intramuscular administration of 1 x ChAdOx1.HTI (5x1010 Vp), 3 x ConM SOSIP.v7 (100μg) adjuvanted with MPLA liposomes (500μg), and 1 x MVA.HTI (2x108pfu)
Study NCT05208125 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline solution
Description: Intramuscular administration of normal saline solution
Study NCT05823922 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician Delivered CBT
Description: Clinicians teach cognitive behavioral therapy (CBT) techniques including emotion monitoring, cognitive restructuring, mindfulness, and exposure to help individuals with anxiety and depression. Participants will attend weekly sessions with their clinician for 6 weeks.
Study NCT05823922 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinician Delivered CBT
Description: Clinicians teach cognitive behavioral therapy (CBT) techniques including emotion monitoring, cognitive restructuring, mindfulness, and exposure to help individuals with anxiety and depression. Participants will attend weekly sessions with their clinician for 6 weeks.
Study NCT05823922 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supplemental MAYA App
Description: The Maya app teaches cognitive behavioral therapy (CBT) techniques including emotion monitoring, cognitive restructuring, mindfulness, and exposure to help individuals with anxiety.~Participants will attend weekly sessions with their clinician as well as using the MAYA application for at least 20 minutes twice a week
Study NCT04818216 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule containing inert ingredient
Study NCT04818216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside
Description: 250 mg Nicotinamide riboside capsules
Study NCT05477251 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lobectomy
Description: lobectomy for GGOs located in hilar regions
Study NCT03324867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular insulin
Description: 40 IU of Humulin-R to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery.
Study NCT03324867 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Flush, 0.9% Injectable Solution
Description: Placebo: Normal Saline to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery
Study NCT04691245 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D US
Description: 3D US guided access to femoral artery
Study NCT04691245 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2D US
Description: 2D US guided access to femoral artery
Study NCT05780801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic Microbiota in Glycerol (10%) (AMG)
Description: Participants with positive MDRO cultures will receive MT instilled via a functional feeding tube when in place or rectal enema (when a functional feeding tube is not present) with the rate adjusted to the recipient's clinical status and infusion tolerance.
Study NCT05072860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid
Description: temporary uterine packing with gauze of the dimensions soaked with 2 gm tranexamic diluted in 60ml saline acid
Study NCT05072860 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: : normal saline
Description: temporary uterine packing with gauze of the dimensions soaked with placebo to 2 gm tranexamic diluted in 60ml saline acid
Study NCT04963855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GT300
Description: SIngle oral dose
Study NCT04963855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline cellulose
Description: placebo
Study NCT06225141 — intervention group
Intervention type: OTHER
Intervention: Clinical Data reuse
Description: Clinical Data reuse
Study NCT05126654 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Partially Hydrolyzed Guar Gum (PHGG)
Description: Partially Hydrolyzed Guar Gum 5 gram/day for 1 month
Study NCT05126654 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Partially Hydrolyzed Guar Gum (PHGG)
Description: Partially Hydrolyzed Guar Gum 5 gram/day for 1 month
Study NCT06456411 — intervention group
Intervention type: PROCEDURE
Intervention: Functional Near-Infrared Spectroscopy
Description: Undergo fNIRS
Study NCT06456411 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06456411 — intervention group
Intervention type: OTHER
Intervention: Virtual Technology Intervention
Description: Undergo relaxation period using VR
Study NCT05178680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: relaxation session combining music and soft light
Description: The caregiver will install a device consisting of a light bubble column, a multicolored light projector, and relaxing music chosen by the patient from a proposed panel. This session will last 30 minutes the day after the surgery
Study NCT05692986 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: A vaginal swab for aerobic and anaerobic cultures before antibiotic administration, 30 minutes after vaginal prep and every hour thereafter until the surgery is completed.
Description: This is a randomized control trial that will compare chlorhexidine vaginal prep with iodine vaginal prep. Our primary outcome will be assessed using a vaginal swab test to look for aerobic and anaerobic cultures. Positive cultures will be defined as colony forming count of >5000cfu. All patients will receive preoperative antibiotics. Patients will receive a vaginal swab for aerobic and anaerobic cultures before antibiotic administration, 30 minutes after vaginal prep and every hour thereafter until the surgery was completed.
Study NCT05064501 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: spirometry
Description: Lung function test: pre and post bronchodilator spirometry
Study NCT05064501 — intervention group
Intervention type: OTHER
Intervention: Asthma control test
Description: Asthma control test
Study NCT06389344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Esketamine ( 50mg, dissolved in 50ml normal saline ) 0.3mg / kg will be infused intravenously at a constant speed within 30 min after tracheal intubation/pneumatectomy fixation.
Study NCT06389344 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Same amount of normal saline will be infused intravenously at a constant speed within 30 min after tracheal intubation/pneumatectomy fixation.
Study NCT05802472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polyphenolic beverage from extract of Vachellia farnesiana
Description: During Visit 2. A single infusion of the polyphenolic extract was administered orally. The dose (1.2 mg/kg body weight) of lyophilized extract, which was diluted in water, was calculated considering each participant's weight.
Study NCT05802472 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During Visit 2. 250 ml of single potable water was administered orally.
Study NCT06554782 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: manual u-shaped toothbrush
Description: manual u-shaped toothbrush with bristles angled 45 degrees to brush upper and lower teeth at the same time
Study NCT05284500 — intervention group
Intervention type: PROCEDURE
Intervention: Pediatric cardiac surgery with cardiopulmonary bypass
Description: All patients undergoing pediatric cardiac surgery with cardiopulmonary bypass will be extracted from our database
Study NCT04775355 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of stool and urine
Study NCT04775355 — intervention group
Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Medical records are reviewed
Study NCT04775355 — intervention group
Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Complete quality of life questionnaires
Study NCT04775355 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT05723692 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALTB-268
Description: monoclonal antibody
Study NCT05723692 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: formulation buffer
Study NCT06541522 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: EIT
Description: Two PEEP titrations monitored by EIT will be performed, each with the electrode belt positioned at a different chest height (2nd intercostal space or 5th intercostal space). The order will be drawn at random.
Study NCT05509556 — intervention group
Intervention type: OTHER
Intervention: talocalcaneal angle measurement
Description: talocalcaneal angle measurement on lateral foot radiographs
Study NCT05961397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: baxdrostat
Description: single oral dose of baxdrostat 10 mg
Study NCT04849676 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: visual neurofeedback
Description: Neurofeedback is a neuromodulatory intervention that does not require applying external stimuli. It relies on displaying participants' brain activity in real time, with the aim of modifying it. Electrical activity (EEG) will be recorded from participants and displayed in real time on a computer screen, in the form of three bars. They will be asked to increase the middle bar, while keeping the side bars low.~The intervention requires training to achieve voluntary control of the targeted brain activity.
Study NCT06317415 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WeChat-based health education on antibiotic use
Description: Health education based on the WeChat platform includes popular science articles on WeChat public Platform and health education videos.
Study NCT06317415 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Regular public health education
Description: Health education information on the prevention and control of common chronic diseases
Study NCT06479291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Oral Tablet
Description: Hydroxychloroquine is taken at the dose of 0.1g / dose, twice a day for 1 year, regardless of food intake.
Study NCT06479291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Participants will take eltrombopag for at least 24 weeks, the dose of eltrombopag is adjusted according to participants' platelet count.
Study NCT06479291 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eltrombopag
Description: Participants will take eltrombopag for at least 24 weeks, the dose of eltrombopag is adjusted according to participants' platelet count.
Study NCT06496425 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: Those randomized to the exercise and music group will receive pre-recorded music playlists along with the exercise. During the strength training (ST), participants will be asked to sync their concentric and eccentric muscle contractions in time with the tempo of playlists. For aerobic exercise (AE), we will adjust the tempo of playlists to match individual walking cadence for participants to be trained to walk in sync with the beats of the playlists.
Study NCT06271681 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 15-valent pneumococcal conjugate vaccine
Description: FDA approved pneumococcal vaccines 15 valent conjugate vaccine administered at enrollment
Study NCT06271681 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 23-valent pneumococcal polysaccharide vaccine
Description: 23 valent pneumococcal vaccine administered 8 weeks after initial 15 valent pneumococcal conjugate vaccine
Study NCT05006989 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blueberry Powder
Description: Administered 10 grams/day
Study NCT05006989 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Powder
Description: Administered 10 grams/day
Study NCT05655221 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: B1344
Description: multi-site abdominal s.c. injections (maximum 2 mL at each site)
Study NCT05655221 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: multi-site abdominal s.c. injections (maximum 2 mL at each site)
Study NCT04771390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selitrectinib (BAY2731954) Adult tablet
Description: Tablet, oral administration
Study NCT04771390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selitrectinib (BAY2731954) Pediatric tablet
Description: Tablet, oral administration
Study NCT04771390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selitrectinib (BAY2731954) Oral solution
Description: Oral solution after reconstitution
Study NCT04771390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selitrectinib (BAY2731954) Oral suspension
Description: Oral suspension after reconstitution
Study NCT05588232 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: scheduled outpatient interventions in interventional cardiology
Description: coronary angiography, coronary angioplasty, peripheral angioplasty (carotid arteries or lower limbs)
Study NCT05588232 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: scheduled outpatient interventions in interventional cardiology
Description: coronary angiography, coronary angioplasty, peripheral angioplasty (carotid arteries or lower limbs)
Study NCT06112392 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Treatment （Stellate ganglion block；Oral standard anti-Parkinson's drugs）
Description: Treatment （Stellate ganglion block；Oral standard anti-Parkinson's drugs）
Study NCT06112392 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Treatment （Oral standard anti-Parkinson's drugs）
Description: Treatment （Oral standard anti-Parkinson's drugs）